In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.